{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:14:14Z","timestamp":1790691254841,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10781-1","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:17:22Z","timestamp":1743013042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-6717","authenticated-orcid":false,"given":"Marwan J.","family":"Alwazzeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-8975","authenticated-orcid":false,"given":"Jumanah","family":"Algazaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9779-8024","authenticated-orcid":false,"given":"Fatimah Ali","family":"Al-Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Alabkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8560","authenticated-orcid":false,"given":"Sara M.","family":"Alwarthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-0281","authenticated-orcid":false,"given":"Mashael","family":"Alhajri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-9462","authenticated-orcid":false,"given":"Bashayer M.","family":"AlShehail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-6002","authenticated-orcid":false,"given":"Amani","family":"Alnimr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5370-9094","authenticated-orcid":false,"given":"Ahmad Wajeeh","family":"Alrefaai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8343-8226","authenticated-orcid":false,"given":"Faten Hussain","family":"Alsaihati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-8391","authenticated-orcid":false,"given":"Fahd Abdulaziz","family":"Almuhanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"12","key":"10781_CR1","volume":"2","author":"MF Lin","year":"2014","unstructured":"Lin MF. Antimicrobial resistance in Acinetobacter baumannii\u202f: from bench to bedside. WJCC. 2014;2(12): 787.","journal-title":"WJCC"},{"issue":"Suppl 7","key":"10781_CR2","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565\u201375.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10781_CR3","first-page":"e00181","volume":"33","author":"DMP De Oliveira","year":"2020","unstructured":"De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3):e00181\u2013219.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10781_CR4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"10781_CR5","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024:ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"9","key":"10781_CR6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333\u201341.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10781_CR7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3947\/ic.2024.0055","volume":"56","author":"SJ Choi","year":"2024","unstructured":"Choi SJ, Kim ES. Optimizing Treatment for Carbapenem-Resistant Acinetobacter baumannii Complex Infections: A Review of Current Evidence. Infect Chemother. 2024;56(2):171\u201387.","journal-title":"Infect Chemother"},{"key":"10781_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103887","volume":"139","author":"A Pormohammad","year":"2020","unstructured":"Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Microb Pathog. 2020;139: 103887.","journal-title":"Microb Pathog"},{"issue":"4","key":"10781_CR9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10781_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10781_CR11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23(9):1072\u201384.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10781_CR12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-060972","volume":"12","author":"RK Kayambankadzanja","year":"2022","unstructured":"Kayambankadzanja RK, Schell CO, Gerdin W\u00e4rnberg M, Tamras T, Mollazadegan H, Holmberg M, et al. Towards definitions of critical illness and critical care using concept analysis. BMJ Open. 2022;12(9): e060972.","journal-title":"BMJ Open"},{"issue":"5","key":"10781_CR13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):575\u201382.","journal-title":"Clin Infect Dis"},{"key":"10781_CR14","unstructured":"European Medicines Agency. European Medicines Agency completes review of polymyxin-based medicines. 2014. Available from:  https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-completes-review-polymyxin-based-medicines."},{"issue":"6","key":"10781_CR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","volume":"138","author":"R Imberti","year":"2010","unstructured":"Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333\u20139.","journal-title":"Chest"},{"issue":"2","key":"10781_CR16","doi-asserted-by":"crossref","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","volume":"8","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K, Bidell MR, Gandhi RG, Alshehri S, Enani MA, Al-Jedai A, et al. Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8(2):ofab026.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10781_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","volume":"42","author":"G Kalin","year":"2014","unstructured":"Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection. 2014;42(1):37\u201342.","journal-title":"Infection"},{"issue":"8","key":"10781_CR18","doi-asserted-by":"crossref","first-page":"908.e1","DOI":"10.1016\/j.cmi.2017.10.033","volume":"24","author":"CA Liang","year":"2018","unstructured":"Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24(8):908.e1-908.e7.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10781_CR19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","volume":"21","author":"A Ardebili","year":"2023","unstructured":"Ardebili A, Izanloo A, Rastegar M. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev Anti Infect Ther. 2023;21(4):387\u2013429.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"10781_CR20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dks084","volume":"67","author":"Y Cai","year":"2012","unstructured":"Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67(7):1607\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"10781_CR21","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2147\/IDR.S234211","volume":"12","author":"H Shi","year":"2019","unstructured":"Shi H, Lee JS, Park SY, Ko Y, Eom JS. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii Pneumonia. Infect Drug Resist. 2019;12:3925\u201334.","journal-title":"Infect Drug Resist"},{"key":"10781_CR22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ijid.2020.05.100","volume":"97","author":"W Katip","year":"2020","unstructured":"Katip W, Uitrakul S, Oberdorfer P. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. Int J Infect Dis. 2020;97:391\u20135.","journal-title":"Int J Infect Dis."},{"issue":"11","key":"10781_CR23","volume":"11","author":"C Huang","year":"2022","unstructured":"Huang C, Chen I, Tang T. Colistin monotherapy versus colistin plus meropenem combination therapy for the treatment of multidrug-resistant acinetobacter baumannii infection: a meta-analysis. J Clin Med. 2022;11(11): 3239.","journal-title":"J Clin Med"},{"key":"10781_CR24","doi-asserted-by":"publisher","unstructured":"Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023;2(1). https:\/\/doi.org\/10.1056\/evidoa2200131.","DOI":"10.1056\/evidoa2200131"},{"issue":"12","key":"10781_CR25","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1007\/s12010-021-03664-z","volume":"193","author":"H Wu","year":"2021","unstructured":"Wu H, Feng H, He L, Zhang H, Xu P. In vitro activities of tigecycline in combination with amikacin or colistin against carbapenem-resistant Acinetobacter baumannii. Appl Biochem Biotechnol. 2021;193(12):3867\u201376.","journal-title":"Appl Biochem Biotechnol"},{"key":"10781_CR26","volume":"14","author":"YC Chuang","year":"2014","unstructured":"Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14: 102.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10781_CR27","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/CCM.0000000000000933","volume":"43","author":"A Cheng","year":"2015","unstructured":"Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015;43(6):1194\u2013204.","journal-title":"Crit Care Med"},{"issue":"7","key":"10781_CR28","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/antibiotics10070880","volume":"10","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Yim J, Nguyen L, Maassen PT, Stamper K, Shiekh Z, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii. Antibiotics (Basel). 2021;10(7):880.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10781_CR29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","volume":"73","author":"K Kengkla","year":"2018","unstructured":"Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22\u201332.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10781_CR30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1248\/bpb.b13-00109","volume":"37","author":"SH Kwon","year":"2014","unstructured":"Kwon SH, Ahn HL, Han OY, La HO. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull. 2014;37(3):340\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10781_CR31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/antibiotics9100647","volume":"9","author":"W Katip","year":"2020","unstructured":"Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics (Basel). 2020;9(10):647.","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"10781_CR32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","volume":"9","author":"GR Yilmaz","year":"2015","unstructured":"Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(5):476\u201385.","journal-title":"J Infect Dev Ctries"},{"issue":"4","key":"10781_CR33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391\u2013400.","journal-title":"Lancet Infect Dis"},{"key":"10781_CR34","doi-asserted-by":"crossref","unstructured":"Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One. 2016;11(3).","DOI":"10.1371\/journal.pone.0150642"},{"issue":"2","key":"10781_CR35","first-page":"103","volume":"23","author":"FJ Candel","year":"2010","unstructured":"Candel FJ, Calvo N, Head J, S\u00e1nchez A, Matesanz M, Culebras E, et al. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter. 2010;23(2):103\u20138.","journal-title":"Rev Esp Quimioter"},{"issue":"6","key":"10781_CR36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","volume":"56","author":"AP Betrosian","year":"2008","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432\u20136.","journal-title":"J Infect"},{"issue":"9","key":"10781_CR37","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1128\/JCM.01194-12","volume":"50","author":"CC Lai","year":"2012","unstructured":"Lai CC, Hsu HL, Tan CK, Tsai HY, Cheng A, Liu CY, et al. Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Clin Microbiol. 2012;50(9):2982\u20136.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10781_CR38","volume":"45","author":"SY Park","year":"2013","unstructured":"Park SY, Choo JW, Kwon SH, Yu SN, Lee EJ, Kim TH, et al. Risk factors for mortality in patients with Acinetobacter baumannii bacteremia. Infect Chemother. 2013;45(3): 325.","journal-title":"Infect Chemother"},{"issue":"2","key":"10781_CR39","first-page":"335","volume":"46","author":"O Karabay","year":"2012","unstructured":"Karabay O, Yahyao\u011flu M, O\u011f\u00fctl\u00fc A, Sand\u0131k\u00e7\u0131 O, Tuna N, Ceylan S. Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients. Mikrobiyol Bul. 2012;46(2):335\u20137.","journal-title":"Mikrobiyol Bul"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10781-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10781-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:18:37Z","timestamp":1743013117000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10781-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10781"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10781-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki of the World Medical Association on ethical principles of medical research. The research project has been approved by the Institutional Review Board (IRB) at Imam Abdulrahman bin Faisal University (IRB-2024\u201301\u2013263). The IRB waived the need for informed consent from the patients involved as the data were analyzed retrospectively and anonymously.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}